scholarly journals Inhibition of dipeptidyl peptidase-4: The mechanisms of action and clinical use of vildagliptin for the management of type 2 diabetes

2009 ◽  
Vol Volume 2 ◽  
pp. 83-90 ◽  
Author(s):  
Adrian Vella ◽  
Galina Smushkin
Keyword(s):  
Type 2 Diabetes ◽  
Dipeptidyl Peptidase ◽  
Mechanisms Of Action ◽  
Clinical Use ◽  
Dipeptidyl Peptidase 4

scholarly journals Ten Years of Vildagliptin

2017 ◽  
Vol 13 (02) ◽  
pp. 54
Author(s):  
Stefano Del Prato ◽  
Keyword(s):  
Type 2 Diabetes ◽  
Endocrine Pancreas ◽  
Dipeptidyl Peptidase ◽  
Clinical Development ◽  
Clinical Use ◽  
Physiological Regulation ◽  
Entire Spectrum ◽  
Dipeptidyl Peptidase 4

After many years of limited therapeutic opportunities, the treatment of type 2 diabetes has become more target and pathophysiologically driven. A typical example is represented by the development of the dipeptidyl peptidase-4 (DPP-4) inhibitors, allowing for more physiological regulation of the endocrine pancreas and leading to a previously unmet risk-to-benefit balance. Vildagliptin, one of the earliest DPP-4 inhibitors, has been tested across the entire spectrum of type 2 diabetes and has been in clinical use for 20 years. This publication critically reviews the main steps in the clinical development of this agent.

scholarly journals Functional foods with dipeptidyl peptidase‐4 inhibitory potential and management of type 2 diabetes: A review

2021 ◽  
Author(s):  
Mutiu Kazeem ◽  
Habeeb Bankole ◽  
Olabisi Ogunrinola ◽  
Adedoja Wusu ◽  
Abidemi Kappo
Keyword(s):  
Type 2 Diabetes ◽  
Functional Foods ◽  
Dipeptidyl Peptidase ◽  
Dipeptidyl Peptidase 4 ◽  
Inhibitory Potential

scholarly journals SAT0583 DIPEPTIDYL PEPTIDASE-4 AND RISK OF PSORIASIS IN PATIENTS WITH TYPE 2 DIABETES

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1250.2-1251
Author(s):  
W. S. Chen ◽  
Y. S. Chang ◽  
C. Y. Tsai ◽  
C. C. Chang
Keyword(s):  
Type 2 Diabetes ◽  
Propensity Score ◽  
Combination Therapy ◽  
Group Versus ◽  
Dipeptidyl Peptidase ◽  
Matched Pair ◽  
Diabetic Patients ◽  
Research Database ◽  
Dipeptidyl Peptidase 4

Background:The risk of psoriasis in diabetic patients has rarely been explored.Objectives:This study aimed to investigate the association between dipeptidyl peptidase-4 (DPP4) inhibitors and the risk of psoriasis in type 2 diabetes mellitus (T2DM) patients.Methods:We conducted a population-based propensity score-matched cohort study on the basis of Taiwan’s National Health Insurance Research Database that included initiators of combination therapy with DPP4i (DPP4i plus metformin) and sulfonylurea (sulfonylurea plus metformin). Psoriasis (PSO) was identified with ≥2 diagnoses. Diabetes complications severity index (DCSI) was calculated. A total of 22721 DPP4 initiator and 227684 sulfonylurea initiator were identified. A 1:10 matched-pair cohort based on propensity score(PS) was created. PS-stratified Cox proportional hazards models compared the risk of PSO in DPP4i versus sulfonylurea initiator within 2 years, controlling for potential confounders.Results:After propensity score matching, 9962 patients with T2DM starting DPP4i combination therapy and 39848 starting sulfonylurea combination therapy were selected. The incidence rate of PSO was lower in DPP4i group (188/100000 person- years) than in sulfonylurea group (467/100000 person-years). Risks of incident psoriasis were significantly lower in the DPP4i group versus sulfonylurea with the PS-stratified HR of 0.422 (95% CI 0.273 to 0.716).Conclusion:DPP4i plus metformin was associated with a reduced risk of psoriasis than sulfonylurea plus metformin. These findings merit further investigation.Disclosure of Interests:None declared

Sign in / Sign up

Export Citation Format

Share Document